Johnson & Johnson is acquiring Halda Therapeutics.

Johnson & Johnson Acquires Halda Therapeutics

Johnson & Johnson (JNJ) has agreed to acquire the privately-held Halda Therapeutics for a cash consideration of $3.05 billion. This acquisition allows the company to expand its cancer portfolio by focusing on solid tumors and prostate cancer. This agreement marks the second largest transaction for Johnson & Johnson this year, following the acquisition of Intra-Cellular Therapies for $14.6 billion.

This deal reinforces Johnson & Johnson's strategy of investing in high-growth areas following the expiration of its monopoly on the highest-selling immune disease treatment, Stelara. In recent years, the company has accelerated its activities in pharmaceuticals and medical devices; it had previously acquired Shockwave Medical for $13.1 billion in 2024.

Halda Therapeutics' leading asset, HLD-0915, is in early to mid-stage development for prostate cancer and is part of a broader pipeline that includes treatment options for breast, lung, and other solid tumors. Analysts noted that this acquisition provides Johnson & Johnson with medium and long-term growth potential for its oncology segment.

Johnson & Johnson stated that Halda has the ability to bind cancer biomarkers to vital proteins through its RiPTAC technology, providing an effective mechanism by targeting these proteins in tumor cells while preserving healthy tissue. The company suggests that the mechanism may be beneficial in combating cancers that do not respond to standard therapies.